Fudan University Shanghai Cancer Center
Shanghai, China
Location contact
Xinxiang Li, MD, PhD
PRINCIPAL_INVESTIGATOR
Yaqi Wang, MD
CONTACT
Zhen Zhang, MD PhD
PRINCIPAL_INVESTIGATOR
Zhen Zhang, MD, PhD
CONTACT
NCT Number: NCT07551479
In this prospective, multicentre, randomized phase III trial, 612 locally advanced rectal cancer (LARC, T3-4/N+M0) patients with at least one high-risk features (lower location (≤5cm), cT4, cN2, MRF+, EMVI+, TD+) will be included, and randomly assigned to TNT group and iTNT group (1:1). TNT group receives long-course chemoradiotherapy (50Gy/25Fx concurrent with oral capecitabine) followed by 6 cycles of CAPOX. iTNT group receives short-course radiotherapy (25Gy/5Fx) followed by 6 cycles of Serplulimab combined with CAPOX. After the efficacy evaluation, the patients who achieves clinical complete response (cCR) will be managed by a watch and wait (W&W) protocol and non-cCR patients will be recommended surgery. The primary endpoint is 3-year event-free survival rate (3yEFS%). The secondary endpoints include the complete response (CR, pathological complete response [pCR] plus cCR) rate, 3-year organ preservation rate, 3-year disease-free survival rate (3yDFS%), 3-year local recurrence free survival rate (3yLRFS%), 3-year distant metastasis free survival rate (3yDMFS%), 3-year overall survival rate (3yOS%), grade 3-4 acute adverse effects (AE) rate, rate of surgical complications, anal functions and quality of life, etc.
Trial opening soon.
Get Notified18 year–75 year
All sexes
Interventional
Phase 3
Shanghai, China
Xinxiang Li, MD, PhD
PRINCIPAL_INVESTIGATOR
Yaqi Wang, MD
CONTACT
Zhen Zhang, MD PhD
PRINCIPAL_INVESTIGATOR
Zhen Zhang, MD, PhD
CONTACT
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
short-course radiaotherapy (25Gy/5Fx)
long-course chemoradiotherapy (50Gy/25Fx concurrent with oral capecitabine 825mg/m2 bid d1-5 qw)
Capecitabine: 1000mg/m2 bid d1-14 q3w
Oxaliplatin 130mg/m2 d1 q3w
Serplulimab 300mg d1 q3w
Time frame: From date of randomization until the date of first documented early local failure, disease progression during neoadjuvant therapy, pelvic recurrence, distant metastasis, or death, whichever came first, assessed up to 36 months.
Rate of 3 year event free survival
Time frame: 1 month after the surgery or the decision of W&W
Rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W&W strategy.
Time frame: From date of randomization until the resection of rectum or anus, assessed up to 36 months.
3 year organ preservation rate
Time frame: From date of randomization until the date of first documented recurrence and metastasis after the completion of treatment or death from any cause, whichever came first, assessed up to 36 months.
Rate of 3 year disease free survival
Time frame: From date of randomization until the date of first documented pelvic failure, assessed up to 36 months.
Rate of 3 year local recurrence free survival
Time frame: From date of randomization until the date of first documented distant metastasis, assessed up to 36 months.
Rate of 3 year distant metastasis free survival
Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months.
Rate of 3 year overall survival
Time frame: From date of randomization until 3 months after the completion neoadjuvant therapy
Rate of chemotherapy, radiotherapy and immunotherapy related adverse events
Time frame: The surgical complications were assessed within 1 year after the surgery.
Rate of surgical complications
Time frame: From date of randomization until five years after the completion of treament.
Evaluating the anal function using Low Anterior Resection Syndrome (LARS) score(range 0-42, with higher scores representing worse anal function)
Time frame: From date of randomization until five years after the completion of treament.
Evaluating the anal function using Wexner Continence Grading Scale (range 1-20, with higher scores representing worse anal function)
Contact information is provided by the study sponsor or research team.
Fudan University
Other
SCRT Followed by CAPOX and PD-1 Inhibitor Versus LCCRT Followed by CAPOX in Total Neoadjuvant Treatment for High-risk LARC: A Prospective, Randomized, Multicenter, Phase III Study
Acronym: TORCH-STAR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07738042
Locally Advanced Rectal Cancer (LARC)
Tianjin, China
View Trial DetailsNCT07581626
Locally Advanced Rectal Cancer (LARC)
Beijing, China
View Trial DetailsNCT07381777
Locally Advanced Rectal Cancer (LARC)
Arezzo, Italy
View Trial DetailsNCT07314528
Body Weight, GLP-1
View Trial Details